Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker

Abstract Introduction Plasma levels of amyloid‐beta (Aβ) do not correlate well with different stages of Alzheimer's disease (AD) in cross‐sectional studies. Measuring the changes in Aβ plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages...

Full description

Bibliographic Details
Main Authors: Esther S. Oh, Christopher M. Marano, Jeannie‐Marie Leoutsakos, Rebecca W. Lee, Robert A. Rissman, Gwenn S. Smith, Suzanne Craft, Constantine G. Lyketsos
Format: Article
Language:English
Published: Wiley 2015-09-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Alzheimer's disease
Blood biomarker
Oral glucose tolerance test
Online Access:https://doi.org/10.1016/j.dadm.2015.06.002

Internet

https://doi.org/10.1016/j.dadm.2015.06.002

Similar Items